DataVXSmallPaper
journal article·2024-05Open access

C60‐based Multivalent Glycoporphyrins Inhibit SARS‐CoV‐2 Specific Interaction with the DC‐SIGN Transmembrane Receptor

Jennifer Patino‐Alonso, Justo Cabrera‐González, Javier Merino, Gema Nieto‐Ortiz, Fátima Lasala, Jouma Katati, Carlos H. Bezerra da Cruz, Ajay K. Monnappa, Pablo Mateos‐Gil, Ángeles Canales, Iván López‐Montero, Beatriz M. Illescas, Rafael Delgado, Nazario Martín

Small· Volume 20· Issue 19
Publisher pageOpen full text
Source abstract

Abstract

Abstract Since WHO has declared the COVID‐19 outbreak a global pandemic, nearly seven million deaths have been reported. This efficient spread of Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) is facilitated by the ability of the spike glycoprotein to bind multiple cell membrane receptors. Although ACE2 is identified as the main receptor for SARS‐CoV‐2, other receptors could play a role in viral entry. Among others, C‐type lectins such as DC‐SIGN are identified as efficient trans‐receptor for SARS‐CoV‐2 infection, so the use of glycomimetics to inhibit the infection through the DC‐SIGN blockade is an encouraging approach. In this regard, multivalent nanostructures based on glycosylated [60]fullerenes linked to a central porphyrin scaffold have been designed and tested against DC‐SIGN‐mediated SARS‐CoV‐2 infection. First results show an outstanding inhibition of the trans‐infection up to 90%. In addition, a deeper understanding of nanostructure‐receptor binding is achieved through microscopy techniques, high‐resolution NMR experiments, Quartz Crystal Microbalance experiments, and molecular dynamic simulations.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Graphene and Nanomaterials Applications · Advanced biosensing and bioanalysis techniques · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Departamento de Química Orgánica Facultad de Química Universidad Complutense Madrid E‐28040 Spain

Departamento de Química en Ciencias Farmacéuticas Facultad de Farmacia Universidad Complutense Madrid E‐28040 Spain

Instituto de Investigación Biomédica Hospital 12 de Octubre (imas12) Madrid 28041 Spain

Departamento de Química Física Facultad de Química Universidad Complutense Madrid E‐28040 Spain

Instituto Pluridisciplinar Paseo Juan XXIII, 1 Madrid 28040 Spain

Departamento de Medicina Facultad de Medicina Universidad Complutense Madrid E‐28040 Spain

Instituto de Salud Carlos III CIBERINFEC Madrid Spain

Campus de Cantoblanco IMDEA‐Nanoscience C/ Faraday 9 Madrid 28049 Spain

Funding

Comunidad de Madrid · Agencia Estatal de Investigación · Spanish National Plan for Scientific and Technical Research and Innovation · European Regional Development Fund

References (48)

Show source-provided references
1. WHO. Coronavirus (COVID‐19) Dashboard https://covid19.who.int/(accessed: February2023).
2. 10.3389/fcimb.2020.0031710.3389/fcimb.2020.00317 ↗
3. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
4. Khodadoost M. · Gastroenterol. Hepatol. Bed Bench. · 2020 · 13 · 374
5. 10.1126/sciadv.abo397710.1126/sciadv.abo3977 ↗
6. 10.1016/j.jbc.2022.10171010.1016/j.jbc.2022.101710 ↗
7. 10.1038/s41586-021-03925-110.1038/s41586-021-03925-1 ↗
8. 10.1021/acscentsci.0c0153710.1021/acscentsci.0c01537 ↗
9. 10.1371/journal.ppat.100957610.1371/journal.ppat.1009576 ↗
10. 10.1126/science.abb998310.1126/science.abb9983 ↗
11. 10.1016/j.cell.2022.12.01810.1016/j.cell.2022.12.018 ↗
12. 10.1039/D2CC00121G10.1039/D2CC00121G ↗
13. 10.1021/jacs.0c0679310.1021/jacs.0c06793 ↗
14. 10.1038/nri118210.1038/nri1182 ↗
15. 10.3390/biology1001000110.3390/biology10010001 ↗
16. 10.1128/JVI.76.13.6841-6844.200210.1128/JVI.76.13.6841-6844.2002 ↗
17. 10.1002/cmdc.20210034810.1002/cmdc.202100348 ↗
18. 10.1021/jacs.1c0677810.1021/jacs.1c06778 ↗
19. 10.1039/c0cc00034e10.1039/c0cc00034e ↗
20. 10.1021/bm301665810.1021/bm3016658 ↗
21. 10.1038/nchem.238710.1038/nchem.2387 ↗
22. 10.1039/C7TB01379E10.1039/C7TB01379E ↗
23. 10.1002/anie.20210422310.1002/anie.202104223 ↗
24. 10.1021/jacs.7b0168310.1021/jacs.7b01683 ↗
25. 10.1021/jacs.9b0800310.1021/jacs.9b08003 ↗
26. 10.3390/ijms2309508310.3390/ijms23095083 ↗
27. 10.1039/C9BM00192A10.1039/C9BM00192A ↗
28. 10.1002/chem.20150461710.1002/chem.201504617 ↗
29. 10.1021/ol702128z10.1021/ol702128z ↗
30. 10.1002/tcr.20140208110.1002/tcr.201402081 ↗
31. 10.1002/1099-0690(200103)2001:5<829::AID-EJOC829>3.0.CO;2-V10.1002/1099-0690(200103)2001:5<829::AID-EJOC829>3.0.CO;2-V ↗
32. 10.1039/C7CC07479D10.1039/C7CC07479D ↗
33. 10.1002/chem.20100281610.1002/chem.201002816 ↗
34. 10.1016/j.jorganchem.2009.02.02010.1016/j.jorganchem.2009.02.020 ↗
35. 10.1142/S108842461100375610.1142/S1088424611003756 ↗
36. 10.1039/b800617b10.1039/b800617b ↗
37. 10.1039/B615067P10.1039/B615067P ↗
38. 10.1002/anie.20030063710.1002/anie.200300637 ↗
39. 10.1021/ja00034a07110.1021/ja00034a071 ↗
40. 10.1039/C5OB00929D10.1039/C5OB00929D ↗
41. 10.1002/anie.20201101510.1002/anie.202011015 ↗
42. 10.1021/acscentsci.0c0153710.1021/acscentsci.0c01537 ↗
43. 10.1021/acschembio.9b0045810.1021/acschembio.9b00458 ↗
44. 10.1021/bi500501410.1021/bi5005014 ↗
45. 10.1002/anie.20170194310.1002/anie.201701943 ↗
46. 10.1039/C6CC02127A10.1039/C6CC02127A ↗
47. 10.1016/B978-0-12-374546-0.00034-110.1016/B978-0-12-374546-0.00034-1 ↗
48. 10.1074/jbc.M60968920010.1074/jbc.M609689200 ↗